FDA Submission for PH-762

Phio Submits FDA Application to Advance Skin Cancer Drug Development

Phio Pharmaceuticals Corp. is preparing to manufacture clinical supplies for the next planned study, expected to be completed in the first quarter of 2027. The company's lead clinical development program is PH-762, a compound that silences the PD-1 gene implicated in various forms of skin cancer. The Phase 1b trial evaluated PH-76 for the treatment of cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinomas. Phio's belief that PH-262 will be a non-surgical treatment for skin cancers is an important step towards unlocking the PH-760 clinical potential in cutaneous Squamous cell cancer. This press release contains forward-looking statements based on current beliefs, expectations and assumptions. However, these statements are subject to numerous factors such as the impact of future FDA interactions on the development of our product candidates, the ability to supply our product candidate for clinical activities if approved, and the potential for commercial use if approved.

Topics